NCT03761914 2024-11-19
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Sellas Life Sciences Group
Phase 1/2 Completed
Clinical Trials
8 trialsNCT02768792 2024-09-25
High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT02981914 2024-04-22
Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation
University of Chicago
Phase EARLY_PHASE1 Completed
NCT02771197 2023-09-28
Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant
Northside Hospital, Inc.
Phase 2 Completed
NCT02845297 2023-03-09
Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02996474 2022-12-28
Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT03144245 2021-10-12
Study of AMV564 in Patients With AML
Amphivena Therapeutics, Inc.
Phase 1 Completed
NCT02708641 2021-08-10
A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AML
University of Pittsburgh
Phase 2 Completed